NACDS In Brief
This article was originally published in The Tan Sheet
Executive Summary
Mentholatum vapor patches: Mentholatum is pulling itsWellPatch Cough and Cold Soothing Vapor Pad from the marketplace following a limited distribution launch and "weak retailer acceptance," the company said at the National Association of Chain Drug Stores Marketplace tradeshow and conference in San Diego, Calif. June 24-27. The patch was indicated for temporary relief of throat and bronchial irritation associated with a cold and provided medicated vapors that would provide relief for up to eight hours. The firm maintains that the product was not pulled for safety reasons. Novartis recently recalled its Triaminic Vapor Patch after adverse events showed the product could be linked to seizures 1("The Tan Sheet" June 26, 2006, p. 8). Mentholatum is, however, gearing up to launch WellPatch Fever. Indicated for fever reduction for both children and adults, a four-count package will be offered for $3.99...
You may also be interested in...
New CortiSlim Line Offers Suite Of SKUs To Boost Energy, Suppress Appetite
The new CortiSlim 360 line of products allows consumers to choose supplements appropriate for their lifestyle and needs, Window Rock Enterprises announced at the recent National Association of Chain Drug Stores Marketplace tradeshow in San Diego, Calif
Triaminic Vapor Patch Adverse Events Prompt Recall By Novartis
Eight complaints of adverse health effects resulting from accidental ingestion of the Triaminic Vapor Patch have prompted a nationwide recall of products in the line by Novartis Consumer Healthcare
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC